We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Troponin Blood Test Offers Quick Method for Monitoring Patients After Cardiac Surgery

By LabMedica International staff writers
Posted on 03 May 2022
Print article
Image: Troponin measurement via blood test a better way to measure risk for heart surgery patients (Photo courtesy of Unsplash)
Image: Troponin measurement via blood test a better way to measure risk for heart surgery patients (Photo courtesy of Unsplash)

Globally about two million adults a year undergo heart surgery and while the procedure prolongs life and improves quality of life, it comes with the risk of serious complications and death. Validating a method with which to predict heart surgery patients most at risk is a big win. A large international study has now identified a first ever marker that is fast and reliable for the monitoring of patients after cardiac surgery.

The study named VISION Cardiac Surgery by researchers at the Population Health Research Institute (PHRI, Hamilton, ON, Canada) has found that the measurement of troponin – a type of protein found in the heart muscle – in patients undergoing heart surgery offers a better way to measure the risk for heart surgery patients. Taken via a simple blood test, troponin was discovered in an earlier study (VISION) to be an effective predictor of risks facing non-cardiac surgery patients. Troponin is not commonly measured after heart surgery, including coronary artery bypass grafting or open-heart surgery such as valve repairs and replacements. As a result, recommendations by medical experts have widely varied (10 to 70 times the lab normal value) regarding troponin levels that define heart attack and one of the most common complications after heart surgery – myocardial injury.

The new study addressing cardiac surgery patients involved 15,984 adult patients (average age just over 63 years) undergoing cardiac surgery. Patients were from 12 countries, more than a third of which were countries outside of North America and Europe. The study team found that by 30 days after heart surgery, 2.1% of patients had died, and 2.9% had experienced a major vascular complication such as heart attack, stroke or life-threatening blot clot.

In the VISION Cardiac Surgery study, “we found that the levels of troponin associated with an increased risk of death within 30 days were substantially higher - 200 to 500 times the normal value - than troponin levels that surgical teams are currently told defines the risk of a patient having myocardial injury,” said PHRI Scientist PJ Devereaux who led the VISION study and was a lead investigator on the new study.

“This study is a landmark for the health teams taking care of patients after cardiac surgery,” added André Lamy, a study investigator, PHRI Scientist and heart surgeon.

“Our findings will help further studies look at the timing of treatments and procedures to improve patient outcomes after heart surgery,” said investigator Richard Whitlock, also a heart surgeon and PHRI Scientist.

Related Links:

Gold Supplier
RIELE Photometer 505
3-DIFF Hematology Analyzer
Benchtop Centrifuge & Vortexer
Silver Supplier
Receptor Destroying Enzyme
RDE II (Receptor Destroying Enzyme)

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.